Myco/Pfizer $50 mil. antifungal drugs R&D agreement is Myco's first major alliance.
MYCO/PFIZER $50 MIL. ANTIFUNGAL R&D COLLABORATION IS EXCLUSIVE for human antifungal drug products, Cambridge, Mass.-based Myco Pharmaceuticals announced March 23. Pfizer will provide Myco with $20 mil. in an equity investment and R&D support over four years, and will make milestone payments that "could exceed $30 mil. if more than one drug is developed," Myco said. The strategic alliance is Myco's biggest deal since the biotech firm's genesis in 1992.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth